ERBB3 and breast cancer: HER-3 overexpression in breast cancer is associated with poor prognosis, and an anti-HER3 ADC therapy, U3-1402, is being studied in a phase I clinical trial on patients with HER-3-positive metastatic breast cancer (NCT02980341) [40].